ARC-10: A phase 3 study to evaluate zimberelimab plus domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non-small-cell lung cancer.

被引：0
|
作者：
Chouaid, Christos
Ho, Gwo Fuang
Runglodvatana, Yotsawaj
He, Xian
Ahlers, Christoph Matthias
Pomponio, Debbie
Todd, Trever
Dang, Thao
Naidoo, Jarushka
机构：
[1] Ctr Hosp Intercommunal Creteil, Creteil, France
[2] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[3] Vajira Hosp, Bangkok, Thailand
[4] Arcus Biosci Inc, Hayward, CA USA
[5] Gilead Sci Inc, Foster City, CA USA
[6] Beaumont Hosp, Dublin, Ireland
[7] RCSI Univ Hlth Sci, Dublin, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9148
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression
    Tambo, Yuichi
    Sone, Takashi
    Shibata, Kazuhiko
    Nishi, Kouichi
    Shirasaki, Hiroki
    Yoneda, Taro
    Araya, Tomoyuki
    Kase, Kazumasa
    Nishikawa, Shingo
    Kimura, Hideharu
    Kasahara, Kazuo
    CLINICAL LUNG CANCER, 2020, 21 (05) : E366 - E379
  • [42] Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
    She, Longjiang
    Hu, Huabin
    Liao, Mengting
    Xia, Xuefeng
    Shi, Yin
    Yao, Linli
    Ding, Dong
    Zhu, Youwen
    Zeng, Shan
    Shen, Liangfang
    Huang, Jin
    Carbone, David P.
    LUNG CANCER, 2019, 138 : 88 - 94
  • [43] Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab'
    Kocak, Mehmet Zahid
    ACTA ONCOLOGICA, 2021, 60 (04) : 564 - 565
  • [44] PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
    Yu, Hui
    Chen, Ping
    Xia, Liangping
    Fu, Sha
    Chen, Chen
    Zhang, Xuanye
    He, Lina
    Zhang, Bei
    Zhou, Yixin
    Hong, Shaodong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [45] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [46] Niraparib (Nira) plus Pembrolizumab (Pembro) Versus Placebo (PBO) plus Pembro first line (1L) Maintenance Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): ZEAL-1L Phase 3 Study
    Schuler, Martin
    Ramalingam, Suresh S.
    Shi, Lei
    Neibauer, Melissa Whipple
    Frenkl, Tara
    Stojadinovic, Alexander
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 152 - 152
  • [47] Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.
    Hamai, Kosuke
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
    Dingemans, A. -M. C.
    de Langen, A. J.
    van den Boogaart, V.
    Marcus, J. T.
    Backes, W. H.
    Scholtens, H. T. G. M.
    van Tinteren, H.
    Hoekstra, O. S.
    Pruim, J.
    Brans, B.
    Thunnissen, F. B.
    Smit, E. F.
    Groen, H. J. M.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 559 - 566
  • [49] Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
    Cardenal, F
    López-Cabrerizo, MP
    Antón, A
    Alberola, V
    Massuti, B
    Carrato, A
    Barneto, I
    Lomas, M
    García, M
    Lianes, P
    Montalar, J
    Vadell, C
    González-Larriba, JL
    Nguyen, B
    Artal, A
    Rosell, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 12 - 18
  • [50] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase 3 ZEAL-1L study
    Nagrial, Adnan
    Ramalingam, Suresh S.
    de Castro, Gilberto, Jr.
    Garassino, Marina Chiara
    Mazieres, Julien
    Sanborn, Rachel
    Smit, Egbert
    Spigel, David R.
    Thomas, Michael
    Velcheti, Vamsidhar
    Shi, Lei
    Neibauer, Melissa Whipple
    Stojadinovic, Alexander
    Peters, Solange
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 204 - 205
12345